Found 5 articles for: "Non-Melanoma"
The Practical Side Effects Experienced in Patients Treated With Medications Approved for Melanoma
May 2025 | Volume 24 | Issue 5 | Features | 539 | Copyright © May 2025
Background: Melanoma continues to remain one of the most feared malignancies among patients and dermatologists. Significant strides have been made in expanding the treatment arse...
Read MoreMetformin Use and Risk of Non-Melanoma Skin Cancer: A Propensity-Matched Case-Control Study
December 2024 | Volume 23 | Issue 12 | Original Article | 1089 | Copyright © December 2024
Background: There is literature that suggests metformin may play a protective role against the development of non-melanoma skin cancers. Given the significant burden of disease n...
Read MoreBeyond the Label: Real-World Side Effects Experienced With FDA-Approved Drugs for Non-Melanoma Skin Cancers
May 2024 | Volume 23 | Issue 5 | Original Article | 301 | Copyright © May 2024
With immunotherapy historically focused on cutaneous melanoma, there has been a new wave of systemic medications available for treating non-melanoma skin cancers including basal cell carcinoma (B...
Read MoreFractional Laser for Prevention of Non-melanoma Skin Cancer
September 2023 | Volume 22 | Issue 9 | Features | 953 | Copyright © September 2023
Citation: McCormick ET, Desai S, Nelson K, et al. Fractional laser for prevention of non-melanoma skin cancer. J Drugs Dermatol. 2023;22(9):953-954. doi:10.36849/JDD.2023.NVRN0923...
Read MoreA Non-Surgical and Cost-Effective Treatment Approach Employing Topical Imiquimod, 5-Fluorouracil, and Tretinoin for Primary Non-Melanoma Skin Cancers
March 2021 | Volume 20 | Issue 3 | Original Article | 260 | Copyright © March 2021
Background: Minimally invasive alternative approaches to treat non-melanoma skin cancers remain limited and unproven.
Objective: We aim to assess the efficacy o...
Read More
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.